New Method Developed for Growing Tissue Engineered Corneas
Sound of Science Podcasts
Fully Enabling Genome-Editing System for Crop Improvement Launched
Novel Tool Combines Computational Platform with a Portfolio of CRISPR 3.0 Genome-Editing Nucleases
Bioprocess Control Specialist Focuses on Single-Use Sensors
Lab Automation through Single-Use Sensors and Monitors
Lonza Upgrades Live-Cell Imaging System
For Obtaining Better Cell-Culture Analyses
Myriad Genetics Trial: Your Thoughts?
The U.S. Supreme Court just delivered a mixed decision for companies looking to patent human genes, ruling against Myriad Genetics’ patent claims for breast cancer susceptibility genes BRCA 1 and 2, but also holding that companies can patent composite DNA (cDNA) and other synthetic genetic material that does not meet the “product of nature” exemption from patentability. How do you feel about this?